Manus seeks $4B valuation in new $500M fundraise as it resumes independent ops
THE SO WHAT
A $4B target valuation and $500M raise for Manus, post-terminated merger, shows capital still believes in independent AI platforms rather than pure acqui-hires. If you’re a mid-stage AI company, this is a green light to pursue scale on your own terms—but expect investors to push hard on defensibility and unit economics.
READ THE SOURCE
MORE FROM THE WIRE
Startups & VentureSpace hardware startup plans $125M stock offering and Nasdaq listing through shell company merger
A Seattle space hardware startup using a reverse takeover and $125M stock offering to reach Nasdaq shows capital markets are reopening to orbital infrastructure—but with creative structures. If you're in space or other capex-heavy tech, you now have one more viable path to liquidity beyond traditional VC and late-stage rounds.
Startups & VentureSoftBank agrees to acquire Robotics and AI Institute
SoftBank consolidating a research-heavy robotics and AI asset under CFIUS review shows frontier autonomy is now squarely in the national-interest bucket. If your roadmap depends on cross-border capital or talent in advanced robotics, assume more friction and longer timelines on strategic deals.
Startups & VentureUK Sovereign AI Fund in talks to back £500m raise for drug discovery startup
If the UK’s sovereign AI vehicle is anchoring a £500m raise into drug discovery, national AI strategy is moving from chips and models into domain-specific IP. Biotech operators should expect more state-backed AI competitors and tighter competition for top applied ML talent.
Startups & VentureImmunology Drugmaker Electra Opens Flat After Upsized US IPO
Electra Therapeutics raising $350m in an upsized IPO but trading flat suggests public markets will fund late-stage biotech, but without the 2021-style pop. Biotech operators should plan for capital access with muted aftermarket enthusiasm—story and pipeline depth matter more than listing optics.